Submit Manuscript  

Editorial Board Members

cdmEditor-in-Chief4832MingHuCollege of PharmacyUniversity of HoustonHoustonTXUnited States

Dr. Ming Hu received Bachelors in Pharmacy from Shanghai First Medical College, Shanghai, China and then obtained Ph.D. in Pharmaceutics from The University of Michigan, Ann Arbor, Michigan. Currently, he is a Professor of Pharmaceutics at the University Of Houston College Of Pharmacy. His research interests include bioavailability of drugs, nutrients, and micronutrients with emphasis on mechanisms of absorption and metabolism of flavonoids and phenolic drugs. Dr. Hu has published several articles in well-reputed journals.
Executive Editor4833Atta-ur-RahmanHonorary Life FellowKings CollegeUniversity of CambridgeCambridgeUnited Kingdom

Prof. Atta-ur-Rahman, Ph.D. in organic chemistry from Kings College, University of Cambridge (1968), has 1235 international publications in several fields of organic chemistry including, 349 books published largely by major U.S. and European presses. He was elected as Fellow of Royal Society (London) (2006) and won the prestigious UNESCO Science Prize (1999). Prof. Atta-ur-Rahman was conferred honorary D.Sc. degrees by many leading world universities including the University of Cambridge and appointed an Honorary Life Fellow of Kings College, University of Cambridge. The Austrian government honoured him with its high civil award (“Grosse Goldene Ehrenzeischen am Bande") (2007). He is Professor Emeritus at the University of Karachi, Pakistan. Prof. Atta-ur-Rahman was appointed Academician (Foreign Member) of the Chinese Academy of Sciences (2015). He won the “Friendship Award of China” (2014) and was conferred the highest scientific award of China, the International Science & Technology Cooperation Award, by President Xi Jinping (2020). He was bestowed with the International Scientific Corporation Award (2014) and the “Einstein Professorship” by the Chinese Academy of Sciences (CAS) (2013). He was also elected as Foreign Member of the Korean Academy of Science and Technology. Research Institutes have been established in his name in China, Malaysia and Pakistan.
Co-Editor4834BaojianWuDivision of PharmaceuticsGuangzhou University of Chinese MedicineGuangzhouChina

Dr. Wu received his B.S. and MSc. degrees from Fudan University, Shanghai, China and a Ph.D. degree from University of Houston. He was then trained as a postdoctoral fellow in biochemistry at Baylor College of Medicine. After over 8 years’ faculty career at College of Pharmacy, Jinan University, he moved to Guangzhou University of Chinese Medicine in 2021. Dr. Wu’s current research interests are circadian rhythms in drug behaviors and diseases, and the underlying mechanisms. He has published over 120 first- or corresponding-authored articles in SCI journals such as Science Advances, Nature communications, Hepatology, Theranostics, and British Journal of Pharmacology.
Associate EditorsASIA4839LeeJiaCancer Metastasis Alert and Prevention Institute, College of Chemistry and Chemical EngineeringFuzhou UniversityFujianChina

Dr. Lee Jia is Distinguished Professor and the founding Director of Cancer Metastasis Alert & Prevention Center at Fuzhou University, China; the Director of Marine Drug R&D Center, Minjiang University, China. He was the Senior Project Officer/ Senior Pharmacologist at NIH/USA. Dr. Jia was elected the Fellow of American Association of Pharmaceutical Scientists (FAAPS; in 2011) as “a distinguished contributor and acknowledged leader in the advancement of the pharmaceutical sciences”, and was the vice-Chair and Chair of the Section of Drug Design & Discovery of AAPS (2009-2012). Jia made his impactful contributions to NO biotechnology, bionanotechnology, cancer metastasis chemoprevention, and Sino-USA bilateral collaborations in researches with >220 peer-reviewed publications (including Science, Nature, Nature Communications, PNAS) and >9400 citations, H-index 40 and i10-index 109 (google scholar). He is recognized as one of the most-cited Chinese scholars by Scopus from 2014-2019. Dr. Jia obtained his PhD in Pharmacology in 1994 under supervision of Dr. Robert Furchgott (the 1998 Nobel Laureate) of the State University of New York, USA. His research interests cover many areas of pharmaceutical sciences.
4838HiroshiYamazakiLaboratory of Drug Metabolism and PharmacokineticsShowa Pharma UniversityMachidaJapan

Dr. Hiroshi Yamazaki has been Professor of Laboratory of Drug Metabolism and Pharmacokinetics at Showa Pharmaceutical University, Tokyo, Japan since 2005. He received his PhD degree from Osaka University in Japan and was trained at Vanderbilt University, TN, USA in 1994. He was a scientist at Osaka Prefectural Institute of Public Health and an Associate Professor of Kanazawa (1998) and Hokkaido (2001) University. He has authored over 340 publications and has been the recipient of the Japanese Society for the Study of Xenobiotics (JSSX) Award and Fellow. He is a member of several editorial committees and the JSSX President-elect (2016-2017).
EUROPE4837Nico P.E.VermeulenDepartment of Chemistry & PharmacochemistryVrije Universiteit AmsterdamAmsterdamNetherlands

Prof. Nico P.E. Vermeulen received a doctorate degree in Chemistry (1975, University of Nijmegen, NL) and a PhD degree in Pharmacology (1980, University of Leiden, NL). He was appointed full professor in Molecular Toxicology at VU University Amsterdam (1985). Currently, he is also Director of AIMMS (Amsterdam Institute for Molecules, Medicines and Systems, at VU University). He is author of > 405 peer reviewed publications and was listed at the ISI list (e.g. 2001 and 2014). He is interested in the roles molecular and computational toxicology and drug metabolism can play in drug discovery, development and safety assessment.
USA4836Albert P.LiResearch and Development DepartmentIn Vitro ADMET LaboratoriesColumbiaMDUnited States

Dr. Li (Ph. D., Biomedical Sciences, University of Tennessee) is President and CEO of In Vitro ADMET Laboratories Inc., Columbia, MD. He was previously Senior Fellow, Monsanto Company; CSO, In Vitro Technologies; Research Professor, St. Louis University Medical School, and CEO, Phase 1 Molecular Toxicology. His research is focused on the development and application of human-based in vitro experimental models in the accurate assessment of human drug properties including metabolic fate, drug-drug interactions and drug toxicity. Dr. Li has published over 170 research articles, book chapters, and reviews, and co-edited 5 books. He holds multiple U.S and international patents.
4835HongbingWangDepartment of Pharmaceutical SciencesUniversity of Maryland School of PharmacyBaltimoreMDUnited States

Dr. Hongbing Wang received his PhD degree from Fudan University Medical Center in China and completed postdoctoral trainings at National Institutes of Environmental Health Sciences, RTP, NC and University of North Carolina at Chapel Hill. He is currently Professor & Program Chair, Experimental and Translational Therapeutics, Department of Pharmaceutical Sciences at University of Maryland School of Pharmacy, Baltimore, Maryland. He has a long-standing interest in studying the function and regulation of xenobiotic-metabolizing enzymes and drug transporters in human liver, drug-induced liver injury, and drug-drug interactions. He has published more than 90 research articles and has severed as a reviewer for many research funding agencies and peer-reviewed journals.
Regional EditorMiddle East4840Mohammad A.KamalKing Fahd Medical Research CenterKing Abdulaziz UniversityJeddahSaudi Arabia

Dr. Mohammad Amjad Kamal is a Distinguished Adjunct Professor at the King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Saudi Arabia. He is leading a highly productive global collaborative research team based on Novel Global Community Educational Foundation (NGCEF), Australia. Dr. Kamal's biochemical research in the field of Alzheimer’s disease, Type 2 diabetes and leukemia has culminated in more than 380 publications in internationally respected journals. Dr. Kamal was awarded a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney. This three years highly competitive award funded his research on the "Inhibition of amido phosphoribosyltransferase by new antifolates". Amongst numerous projects, Dr. Kamal also collaborated on the molecular biological research project “Linkage of Alzheimer’s disease and Type 2 diabetes” at the University of Technology, Sydney. Moreover, he is serving as an EiC/regional/editorial member/guest editor of several reputed scientific journals on honorable basis.
Section Editors7856SuZengDepartment of Pharmaceutical SciencesZhejiang UniversityHangzhouChina

Dr. Su Zeng is the Director at the Institute of Drug Metabolism and Pharmaceutical Analysis. He is the Associate Director at the Faculty of Medicine and Pharmacy. He is the Professor at the College of Pharmaceutical Sciences, Zhejiang University, China. Dr. Zeng received his Bachelor and Master Degree from Zhejiang Medical University in 1982 and 1986, respectively. He worked at Center for Human Toxicology, University of Utah, USA from 1990 to 1992. He did PhD from Zhejiang University in 1999. Dr. Zeng also serves as an Associate Editor of J Pharm Anal, J Chin Pharm Sic, Chin J Pharm Anal, Chin Modern Applied Pharmacy and a member of the editorial board of in a number of journals. His research is focused on the mechanism of drug ADME/T by using epigenetic models, transgenic cells expressing drug metabolizing enzymes or transporters.

Drug Metabolizing
7395KazimSahinNutrition Veterinary FacultyFirat UniversityElazigTurkey

Professor Dr. Kazim Şahin graduated from Veterinary Faculty, Ankara University in 1990. He is a Professor at the Department of Nutrition, Firat University. He is a Principal Member of the Turkish Academy of Sciences and chair of the Food, Nutrition and Health Working Group of the Turkish Academy of Sciences. He is also a Diplomat of European College of Poultry Veterinary Science and has been actively involved in international research projects and conferences along with renowned scientists in World including USA, Germany, Austria, Poland and Belgium. Dr. Sahin was given the “Scientific Award” by The Scientific and Technological Research Council of Turkey (TÜBİTAK) in 2019. He has over 276 publications (SCI or SCI-Expanded) in highly selected peer-reviewed journals with high impact factors. He served as the Chairman of the Organizing Committee and memberships in many international congresses.

Editorial Board Members4847BinGuoKey Laboratory of Phytochemical R&D of Hunan ProvinceHunan Normal UniversityChangshaChina

Dr. Bin Guo is currently a Professor at the Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University. His research interests are towards bioactivation of a foreign chemical, mass spectrometry-based probing of reactive metabolite profiles and their chemical modifications to biomolecules. He did Ph.D. (majoring in Drug Metabolism and Pharmacokinetics) from Shanghai Institute of Materia Medica (SIMM), CAS in 2005. He has authored over 30 research papers, 5 review articles, 3 book chapters and 5 issued patents.
4856Beshay N.M.ZordokyDepartment of Experimental and Clinical PharmacologyUniversity of MinnesotaMinneapolisMNUnited States

Dr. Beshay Zordoky has completed his PhD in pharmaceutical sciences and his postdoctoral training in cardiovascular research from University of Alberta, Canada. He is currently an assistant professor in the department of Experimental and Clinical Pharmacology, University of Minnesota, USA. He has published 31 papers, one book chapter, and more than 35 abstracts (h-index of 21). He has been serving as a reviewer and an editorial board member of a number of reputable journals. His research interests include cardio-oncology, cardiovascular pharmacology, and drug metabolism.
4850Huang-PingYuDepartment of AnesthesiologyChang Gung Memorial HospitalTaoyuanTaiwan

Professor Huang-Ping Yu, MD, PhD, works as the Professor and Chairman of Department of Anesthesiology and Vice Chairman of Committee of Medical Research Evaluation of Chang Gung Medical Center (around 3,700 ward beds). In addition, Professor Yu is appointed as the member of Editorial Board of international ‘SHOCK’ journal and associate Editor of Asian Journal of Anesthesiology. He has over 110 publications of book chapters, original articles and review papers being published in the English peer review journals. Professor Yu’s studies investigating the mechanism of therapeutic reagents-induced improvement of organ function and the potential use of therapeutic reagents after trauma/sepsis to prevent organ dysfunction, therefore represent a novel and innovative approach for maintaining organ function under those conditions.
4846JieXingSchool of Pharmaceutical SciencesShandong UniversityJinanChina

Dr. Jie Xing did PhD from Laboratory of Drug Metabolism and Pharmacokinetics from the School of Pharmacy, Shenyang Pharmaceutical University, China in 2005. She is currently a Professor at the Department of Pharmaceutical Sciences, Shandong University, P.R. China. Dr. Xing has around 23 publications to her credit so far.
4855A.C.SilvaFaculty of PharmacyUniversity of Porto and Fernando Pessoa UniversityPortoPortugal

Dr. Silva is an Assistant Professor of Pharmaceutical Technology and Biotechnology and a Researcher at CEBIMED, FP-ENAS, University Fernando Pessoa, Porto, Portugal. She is also an Invited Professor and Researcher at UCIBIO, ReQuimTe, Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Portugal. She received her PhD in Pharmaceutical Sciences (specialization in Pharmaceutical Technology) from the University of Porto and Graduation in Pharmaceutical Sciences from the University Fernando Pessoa. Her current research interests are: development of new delivery systems for oral, cutaneous and nasal administration of drugs and biopharmaceuticals. Dr. Silva is an Author and reviewer for several international scientific journals in the area of Pharmaceutical Technology and Biotechnology. Supervisor and co-supervisor of PhD, MSc and Undergraduate students.
4841Syed S.AgaDepartment of Basic Medical SciencesKing Saud Bin Abdulaziz UniversityJeddahSaudi Arabia

Currently, Dr. Aga is working as Assistant Professor of Biochemistry (Since May, 2015) in the Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, KSA. He has a research experience of almost 12 years in the field of cancer genetics and molecular biology. He has published almost 75 scientific papers in the well-reputed national and international journals on wide variety of topics including Genetics, Molecular Biology, Oncology, Biochemistry and Colorectal, Breast, Prostate, Esophageal & Bladder Cancer. In many of them, he was eitherthe first, or the corresponding author. Currently, the citation index (h) of his articles is 20 and i10 is 37.
4860HaipingHaoCollege of PharmacyChina Pharmaceutical UniversityNanjingChina

Dr. Hao obtained his Ph.D. degree in Drug Metabolism and Pharmacokinetics from China Pharmaceutical University. Currently Dr. Hao is a professor and the dean of School of Pharmacy in China Pharmaceutical University. His research mainly covers the molecular mechanisms of drug disposition and metabolic regulation guided target discovery. He has published more than 120 scientific publications and is currently an editor of this journal.
4868William G.HumphreysDepartment of BiotransformationBristol-Myers SquibbPrincetonNJUnited States

Dr. Griff Humphreys is currently Senior Research Fellow in the Department of Metabolism and Pharmacokinetics at Bristol-Myers Squibb. He received his graduate training in chemistry at the University of Virginia and completed post-doctoral training at the Center in Molecular Toxicology at Vanderbilt University. His interests include the consequences of reactive metabolite formation, development of new analytical methodologies, reaction phenotyping of CYP and UGT catalyzed biotransformations, identification of endogenous probes for ADME-related protein function, predictive metabolism and toxicology models, in vitro-in vivo correlations, and strategies for candidate optimization.
4845RameshJayaramanTheraIndx Lifesciences Pvt LtdBangaloreIndia

Ramesh Jayaraman is a Drug Discovery scientist with expertise in Pharmacokinetics, Pharmacodynamics and Preclinical development and has worked in the field of drug discovery and development for the last twenty four years. He has been part of Lead identification, optimization and product development teams in large and medium pharmaceutical companies. He is currently the co-founder and the Chief Scientific Officer of TheraIndx Lifesciences, India. He is responsible for overseeing the scientific projects at TheraIndx. At S*BIO (Singapore), as a senior scientist of preclinical development, he worked on preclinical ADME, PK, preclinical development and clinical pharmacokinetics of small molecule targeted anti-cancer agents such as Pacritinib (SB1518 - in phase 3 clincial trials), Pracinostat (SB939 - in phase 2 clinical trials), SB1317 (in phase 1 clincial trials) and SB1578(Phase1clinical trials)
4854SupratikKarDepartment of Chemistry, Physics and Atmospheric SciencesJackson State UniversityJacksonMSUnited States

Dr. Supratik Kar is a research associate at Jackson State University, Mississippi, USA. He has completed his B. Pharm. (2008) and M. Pharm. (2010) degree from Jadavpur University (Kolkata, India) securing first position in both degrees and earned his PhD (2015) from the Jadavpur University (Kolkata, India). He is a Former visiting researcher at the University of Gdańsk (Poland). Dr. Kar has been working and gaining experience in molecular modeling studies for ten years. He has published 50 research and review articles, 9 book chapters till date with h-index 20. He has also co-authored 2 QSAR related books in Academic press and Springer. He is also the Reviewer of more than 15 reputed journals.
4866HansruediGlattDepartment of Nutritional ToxicologyGerman Institute of Human Nutrition (DIfE)NuthetalGermany

Hansruedi Glatt obtained a Ph.D. in biology from the University of Basle. He was Professor for Toxicology and Pharmacology at the University of Mainz (1987-1994), Professor for Molecular Toxicology at the University of Potsdam (1994-2013) and Head of the Department of Nutritional Toxicology at the German Institute of Human Nutrition (1994-2013). He also teaches in the Master Program in Toxicology at the Charité Berlin (since 2008) and is Senior Professor at the Federal Institute of Risk Assessment (since 2014). He has published nearly 290 articles in scientific journals and 85 book chapters.
4859MatthewSoarsMetabolism and Pharmacokinetics DepartmentBristol-Myers SquibbWallingfordCTUnited States

Dr Soars is a Senior Principal Scientist in the Metabolism and Pharmacokinetics department at Bristol-Myers Squibb in Wallingford CT. He received his Bachelors in biochemistry from the University of Warwick in 1998 and a Phd from the University of Dundee in 2002. From 2002-2003, he completed a postdoctoral fellowship at Eli Lilly where he worked on drug glucuronidation under the supervision of Steve Wrighton. He then moved to AstraZeneca where he worked for 8 years developing and implementing both drug metabolism assays and more recently transporter methodology. Since 2011 Dr. Soars has worked at Bristol –Myers Squibb where he helped develop the transporter strategy in Drug Discovery. Research interests include the prediction of pharmacokinetics and drug-drug interactions for new chemical entities and also the application of drug transporter methodology in early Drug Discovery. Dr Soars has published more than 30 scientific publications and is on the Editorial advisory board for a number of publications including Xenobiotica, Current Drug Metabolism and Drug Metabolism letters.
4873MertUlgenThe School of Associated Health Sciences Maltepe CampusAcibadem UniversityIstanbulTurkey

Prof. Dr. Mert Ulgen graduated from Marmara University, Faculty of Pharmacy, Istanbul, Turkey in 1981. He finished his MSc degree from the same department and in 1992, he obtained a PhD degree from University of London, King's College, Biopharmacy Department in the area of Drug Metabolism. He returned to Turkey and became an associated Professor in 1993 and a full professor in 1999 at the same department in the area of Pharmaceutical Chemistry. He got a number of papers on drug synthesis and in vitro hepatic microsomal metabolism of xenobiotics. He directed a number of MSc and PhD thesis. He retired from Marmara University in June 2009 and he became a full time Professor at Acıbadem University, Vocational School of Health Services in the same year. He has a number of administrative duties. He is also a full time chemistry lecturer. He was Director of Institute of Health Sciences in Acıbadem University one term (2013-2016). He established Faculty of Pharmacy at the same University in early 2016 and he is currently dean of Pharmacy. He is also head of "Management in Drug Industry" MSc Program.
4865ChunyingChenCAS Key Laboratory for Biomedical Effects of Nanomaterials and NanosafetyNational Center for Nanoscience and TechnologyBeijingChina

Dr. Chen obtained her Ph.D. degree in Biomedical engineering from Huazhong University of Science and Technology of China (1996). She is one of the earliest researchers in the field of nanosafety in China. Dr. Chen currently is a principal investigator at CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety in the National Center for Nanoscience and Technology of China. She has authored/co-authored over 150 peer-reviewed papers /book chapters, has more than ten issued patents and finished one ISO standard. She has been awarded the Second Prize of the National Natural Science Awards (2012), China Outstanding Young Female Scientists Awards (2014) and the National Science Fund for Distinguished Young Scholars (2014).
4872Babu L.TekwaniDepartment of PharmacologyUniversity of MississippiOxfordMSUnited States

Principal Scientist & Professor of Pharmacology, National Center for Natural Products Research (NCNPR), School of Pharmacy, University of Mississippi, University, MS, USA. Leading Molecular Parasitology and in vitro/in vivo screening research related to the antiparasitic drug discovery programs at the NCNPR. Coordinator and Co-PI collaborative UM (NCNPR) and Walter Reed Army Institute of Research (WRAIR) drug discovery program (2001-till date).Focus of Research- Biochemistry and molecular biology of tropical disease pathogens (malaria, leishmaniasis and trypanosomiasis); Drug Metabolism; Neurodegenerative disorders; New drug discovery research; Pharmacokinetics, In vitro–in vivo drug metabolism, Molecular and functional characterization of potential targets enzymes, genes and metabolic pathways from malaria and leishmania parasites.
4844TadatoshiTaninoFaculty of Pharmaceutical SciencesTokushima Bunri UniversityTokushimaJapan

Dr. Tadatoshi Tanino has been associate professor of Laboratory of Pharmaceutics at Tokushima Bunri University, Tokushima Japan. He received his PhD degree from Kinki University in Japan and was trained at the University of Toronto (Prof. Dr. Jack Utreacht), ON, Canada in 2010- 2011. Now, his primary research interests are gas messenger-dependent drug pharmacokinetics and liver damage. He has published over 60 papers in SCI journals such as Biochem Pharmacol, Drug Metab Dispos, Pharm Res, Cancer Letters, J Drug Targeting, J Pharm Sci, and Chem Res in Toxicol.
4853Su-JunLeeDepartment of Pharmacology, Pharmacogenomics Research CenterInje UniversityBusanSouth Korea

Dr. Su-Jun Lee received his PhD degree in Toxicology from Oregon State University, USA and finished his post-doctoral research fellow in NIH, USA. Dr. Su-Jun Lee has been professor of Department of Pharmacology at Inje University College of Medicine, Inje University, Korea since 2006. He has authored over 50 publications and several book chapters. He has been serving as a reviewer and an editorial board member for a number of journals. His research interest includes pharmacogenomics, functional genomics, drug metabolism, and molecular toxicology.
4858HuileGaoDepartment of PharmaceuticsSchool of PharmacyFudan UniversityChengduChina

Dr. Huile Gao received his PhD in Pharmaceutics from School of Pharmacy, Fudan University in 2013 under the supervision of Prof. Xinguo Jiang. Then he joined the West China School of Pharmacy, Sichuan University as an Instructor in July 2013 and was promoted to an Associate Professor in July 2014. Dr. Gao’s research interests focus on the design, synthesis, characterization and evaluation of stimuli responsive nanomaterials for drug and imaging probe delivery to improve treatment and diagnosis of human diseases especially tumor and brain diseases. He has published over 80 peer-reviewed articles with an H-index of 28.
4852YoshihiroUesawaDepartment of Medical Molecular InformaticsMeiji Pharmaceutical UniversityTokyoJapan

Yoshihiro Uesawa received his Ph.D. degree from the Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan, in 1992. He is a Professor at Meiji Pharmaceutical University, Tokyo, Japan. His major areas of research are related to computational toxicology, pharmaceutical interactions between medications and foods, analyses of quantitative structure-activity relationships (QSAR), machine learning, and data mining. In September of 2009, he became a first-pass winner in the CADASTER Environmental Toxicity Prediction Challenge, organized by ICANN’09: International Conference on Artificial Neural Networks, European Neural Network Society and CADASTER project. In addition, in January 2015, he became one of the winners in the “Tox21 DATA Challenge 2014”, organized by NIH, USA.
4849SeiichiIshidaDivision of PharmacologyNational Institute of Health SciencesKawasakiJapan

Seiichi Ishida is Section Chief at Division of Pharmacology at National Institute of Health Sciences. He received his PhD in Pharmaceutical Science from the University of Tokyo, Japan in 1993, and conducted postdoctoral studies at The Cancer Institute (Tokyo) and at Howard Hughes Medical Institute at Duke University Medical Centre. His research focuses primarily on the development of in vitro cell assay platform for the evaluation of drug metabolism and drug induced liver injury and their application to the regulatory science field.
4864JohnCashmanHuman BioMolecular Research InstituteSan DiegoCAUnited States

John R. Cashman, Ph.D., President, has more than 30 years experience in biomedical research. In 1997, he founded the Human BioMolecular Research Institute to do fundamental and applied research to address human diseases. Previously, he was at the Seattle Biomedical Research Institute, was Associate Director for the IGEN Research Institute and was Assistant Professor of Pharmaceutical Chemistry at UC San Francisco. He was a postdoc with Professor E.J. Corey (1982-1984). Dr. Cashman received his Bachelors degree in chemistry and biology at the College of Creative Studies, UC Santa Barbara (1977), MS and then Ph.D. in Medicinal Chemistry from the University of Kansas (1982). Dr. Cashman is the author of over 240 research articles, book chapters and patents in drug discovery and evaluation.
4871ChandraPrakashDrug Metabolism and PharmacokineticsCP Pharma Consulting, LLCMAUnited States

Dr. Prakash is a Senior Research Fellow in Drug Metabolism, Pharmacokinetics and Clinical Pharmacology department at Agios, Cambridge, MA. Prior to joining Agios, he worked at Vanderbilt University, Pfizer Global Research and Development and Bogen. For the last 30 years, Dr. Prakash has been involved in the drug metabolism and clinical pharmacology studies to support drug discovery, development and registration. His research is primarily focused on the development and utilization of novel approaches and techniques to assess the metabolism and toxicological aspects of the new chemical entities. He is the author of more than 265 manuscripts, book chapters, presentations and patents.
4843Martin KrøyerRasmussenDepartment of Food ScienceAarhus UniversityAarhusDenmark

Dr. Martin Krøyer Rasmussen has completed his PhD in food sciences from Department of Food Science, Aarhus University, Denmark. He did his post-doctoral training both at University of Montpellier, France and Aarhus University, Denmark. He is currently an assistant professor in the department of food science, Aarhus University, Denmark. He has published 47 papers and more than 30 abstracts. His research interests includes regulation of human and porcine cytochrome p450s, food-drug interactions and cell culturing

4848YiLuDepartment of PharmaceuticsFudan UniversityShanghaiChina

Dr. Yi Lu received his Ph.D. in Pharmaceutics from Sichuan University in 2006 and joined Fudan University after graduation. In 2011, he was promoted to be an associate professor. Dr. Lu’s research interests include nano-drug delivery systems, transdermal drug delivery systems and nanocrystals. Recently, he developed self-discriminative hybrid nanocrystals with ACQ fluorescent probes to explore in vivo fate of nanocrystals. He has published more than 90 peer-reviewed articles in SCI journals, five book chapters, and has applied for seven patents. Dr. Lu is also editorial board member of Journal of Basic and Clinical Pharmacy and Chinese Chemical Letters.
4857Upendra A.ArgikarAnalytical Sciences and ImagingNovartis Institutes for BioMedical Research, Inc.CambridgeMAUnited States

Upendra A. Argikar is a Senior Research Investigator at Novartis Institutes for Biomedical Research, Inc. in Cambridge, Massachusetts, USA. He received a Ph.D. in Medicinal Chemistry from University of Minnesota, USA. He has 15+ years of research experience in drug metabolism and pharmacokinetics. At Novartis he has been an active member of projects spanning many disease areas. Currently, he focuses on metabolite identification and structure elucidation of new chemical entities and clinical candidates. Upendra has continued to be interested in conjugative metabolism by uridine diphospho-glucuronosyl transferases, a topic on which he has co-authored research articles, reviews, and book chapters.
4851JunboXieTraditional Chinese MedicineTianjin University of Traditional Chinese MedicineTianjinChina

Dr. Xie is currently a professor of Tianjin University of Traditional Chinese Medicine. His research mainly covers the metabolism, pharmacokinetics and molecular mechanisms of drug (especially herbal bioactive components, including polysaccharide, saponis, flavonoids, et al). In addition, he also focused on the development of new techniques (such as biosensors) for evaluating the safty and bioactivity of the drug. He has published more than 100 scientific publications and is currently an editor of this journal.
4863Suresh K.BalaniDrug Metabolism and Pharmacokinetics DepartmentTakeda Pharmaceuticals International CompanyCambridgeMAUnited Statessuresh.balani@takeda.com4870EthirajuluKantharajADME/Tox DepartmentR & D Technical, D3, A*STARSingapore

Ethirajulu Kantharaj currently works at D3, A*STAR, Singapore as Head of Technical, R & D. He is a professional drug discovery & development leader with 21 years of experience in DMPK, CMC and Toxicology and early drug development across therapy areas in both small biotech and large pharmaceutical setting. In D3, he is responsible for all the preclinical development activities starting from preclinical development candidate to IND submissions. He was involved in the preclinical development of several NMEs leading to successful INDs in USA and regulatory submissions in Singapore and Australia enabling start of clinical studies. He also strategized successful regulatory meetings with both US (FDA) and EU (EMA) for seeking agreements on the non-clinical development plans and strategy from pre-IND stages to advanced clinical development stages. Previously, Dr Ethirajulu has worked with S*BIO Pte Ltd, Johnson & Johnson Pharmaceutical Research and Development as team leader, ADME/Tox department and AstraZeneca R&D as Head of DMPK and Bioanalytical Chemistry.
4842Nigel J.WatersPreclinical DevelopmentBlack Diamond TherapeuticsCambridgeMAUnited States

Nigel Waters is currently a Vice President of Preclinical Development at Black Diamond Therapeutics and has 20 years of pharmaceutical R&D experience. He received his undergraduate degree in Biochemistry at Imperial College London, a Ph.D. in Chemistry at Imperial College London, and is a Diplomate of the American Board of Toxicology (DABT). He has co-authored more than 50 peer-reviewed papers, book chapters, and patents, in the areas of drug discovery, drug metabolism, clinical pharmacology, and preclinical safety assessment.
4861JianboXiaoDepartment of Analytical Chemistry and Food ScienceUniversity of VigoVigoSpain

Dr. Jianbo Xiao is current a full professor of Faculty of Food Science and Technology, University of Vigo (Spain). He received PhD degree in nutrition from Okayama Prefectural University (Japan) in 2009. He worked as a Postdoc supported by AvH foundation at University of Würzbug, Germany (April 2013-May 2015) and then worked as an assistant professor in University of Macau (October 2015-December 2020). Dr. Xiao has been selected as Clarivate Analytics Highly Cited Researchers (2016, 2017, 2019 and 2020). His research is focusing on dietary polyphenols. He has accepted and published more than 300 peer reviewed papers including Nature Reviews Drug Discovery, Seminars in Cancer Biology, Biotechnology Advances, Medicinal Research Reviews, Trends in Food Science & Technology, Critical Reviews in Food Science and Nutrition, Acta Pharmaceutica Sinica B, Journal of Advanced Research, Food Chemistry, Food and Chemical Toxicology, Molecular Nutrition and Food Research, Journal of Agricultural and Food Chemistry and so on (Scopus citation: 8698, H-index 49; Google citation: 11386, H-index 56). He also works as the chairman to organize ISPMF2015, 2-ISPMF (2017), 3-ISPMF (2018), and 4-ISPMF (2020). Dr. Xiao has given 5 plenary lectures, 12 invited lectures and 15 oral presentations on international conferences. Dr. Xiao has hosted more than 12 research grants and since 2009. Dr. Xiao is the expert Reviewer of European Science Foundation, UK Diabetes Foundation (UK), Natural Science Foundation of China (China), the Italian Ministry for Education, University and Research (Italy). Dr. Xiao was elected to full membership of Sigma Xi Scientific Research Honor Society (USA).
4869MahmudKajbafDrug Metabolism DivisionAptuit FlemingVeronaItaly

Dr Mahmud Kajbaf holds a Ph.D. from the University of London, King’s College, Biopharmacy Department in the area of drug metabolism and MSc from Aston University, Birmingham. Currently Dr Kajbaf is Senior Scientist at Aptuit. He has received several awards and honors, such as: Aptuit CEO Excellence Award, GlaxoSmithKline the psychiatry CEDD Leadership Team Award. He is also on the editorial board for several journals. He has published over 33 research articles related to drug metabolism, in vivo-in vitro correlation, drug-drug interaction, HPLC, NMR and mass spectrometry.
Associate Editorial Board Members4874Guillermog AlbertoKellerPharmacogenomics & Personalized Medicine Laboratory, Drug Surveillance & Safety Center, School of MedicineUniversidad de Buenos AiresBuenos AiresArgentina

Dr. Guillermo Alberto Keller is professor of pharmacology (University of Buenos Aires and Favaloro University), training coordinator in clinical pharmacology, coordinator of pharmacovigilance programs, and chief of emergency department at a Santojanni General Hospital (Buenos Aires). Dr. Keller serves as a member of the ethics committee of the Faculty of Medicine of the University of Buenos Aires, and as a guest editor of several reputed scientific journals on an honorable basis. His research is focused on clinical pharmacokinetics, population PK modeling, pharmacometrics aiming to explain PK variability in various drugs and Drug Safety.
4877KatarinaVucicevicFaculty of PharmacyUniversity of BelgradeBelgradeSerbia

Dr. Katarina Vucicevic (PhD in Pharmacokinetics) is associate professor at University of Belgrade - Faculty of Pharmacy. As a Fulbright scholar she spent one year at UCSF, USA advancing her skills and expertise in PKPD modeling. Her research is focused on clinical pharmacokinetics, population PKPD modeling, pharmacometrics aiming to explain PK and PD variability in various drugs. Dr. Vucicevic has published over 35 research articles and reviews, co-author of university book in pharmacokinetics and she has contributed to multiple book chapters.
4876Jonathan P.MochelDepartment of Biomedical SciencesIowa State UniversityAmesIAUnited States

Dr. Mochel is a Principal Investigator with a broad background in clinical and basic Pharmacology sciences, serving as a board-certified veterinary pharmacologist and toxicologist (DECVPT) in the Department of Biomedical Sciences at Iowa State University. Dr. Mochel has extensive post-graduate training in Pharmacology (MS), Pharmacokinetics (MS), and applied Mathematical Modeling (PhD) and he currently chairs the Education and Residency Committee of the College of Veterinary Pharmacology and Toxicology (ECVPT). In addition, Dr. Mochel has in-depth experience in Drug Research and Development, working for about 10 years in the human pharmaceutical industry (both at Novartis and Roche), which provides him with the necessary background to evaluate the efficacy and safety of candidate drugs used in animal systems and human patients. Dr. Mochel is currently a Councilor and Fellow of the American Academy of Veterinary Pharmacology and Therapeutics.
4875Volker M.LauschkeMicro- and Nanoengineering FacilityKarolinska InstitutetStockholmSweden

Dr. Volker Lauschke is Associate Professor and group leader in Personalized Medicine and Drug Development as well as Director of the Microfluidics Facility at Karolinska Institutet, Stockholm, Sweden. His research group uses 3D cell culture systems of primary human cells, microfluidics and integrative bioinformatics approaches to predict drug toxicity and to identify novel therapeutic strategies for complex metabolic diseases. Furthermore, the lab develops artificial intelligence tools to improve personalized pharmacological therapy. Dr. Lauschke is an Oversea Fellow of the Royal Society of Medicine and awardee of the Lennart Philipson Award. In addition, he is co-founder and CEO of HepaPredict AB, a biotech company offering evaluations of drug metabolism and safety as well as drug target validations based on a novel microphysiological 3D spheroid culture platform.
Executive Guest Editors4880WeiCaiSchool of Pharmaceutical ScienceHunan University of MedicineChangshaChina

Dr. Wei Cai received his Ph.D degree from Beijing University of Chinese Medicine in 2015. He is currently an associate professor at school of pharmaceutical science, Hunan University of Medicine. During 2017-2018, he was a visiting scholar at Yale University under the supervision of Prof. Yung-Chi Cheng. He is especially interested in metabolism and pharmacokinetics of traditional Chinese medicine. He has published more than 30 peer-reviewed papers.
4894Pereira S.PereiraDepartment of AntibioticsUniversidade Regional do CaririCratoBrazil

Dr. Pereira graduated in Biological Sciences from the Regional University of Cariri (URCA). Dr. Pereira obtained a PhD in Biotechnology from the Federal University of Pernambuco (UFPE-RENORBIO. He has experience in Microbiology, Toxicology of Natural and Synthetic Products and Biosafety, acting on the following subjects: antibacterial activity, inflammation, toxicity and cancer. He is also a reviewer for several international journals.
4886TatsuyaNaganoGraduate School of MedicineKobe UniversityKobeJapan

Dr. Nagano obtained a Ph.D. from the Kobe University Graduate School of Medicine (Kobe, Japan). Dr. Nagano also received M.D. from the Kobe University Graduate School of Medicine and has a 17 years’ experience as physician in general hospital. Currently Dr. Nagano is an Assistant Professor in the Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine. His present research field is clinical pharmacology in cancer pharmacotherapy. He has published more than 40 scientific publications and has 1 patent. Dr. Fujita is currently the Executive Guest Editor of this journal (Current Drug Metabolism).
4879HilmiOrhanToxicology DepartmentEge UniversityIzmirTurkey

Hilmi Orhan is a Professor in the Department of Toxicology at Ege University, Izmir, Turkey. He obtained his Ph.D. in Pharmaceutical Toxicology from Hacettepe University in 2000. He was a visiting fellow at Vrije Universiteit, The Netherlands in 1995. During his Ph.D., he received a Turkish Scientific and Technical Research Council (TUBITAK) /NATO A2 grant and researched the Division of Molecular Toxicology from the same university on the biotransformation and toxicity of volatile anesthetics (1997–1999). Dr. Orhan has authored or co-authored 40 publications in peer-reviewed international journals and 18 publications in local journals. He has taught toxicology to both graduate and undergraduate levels and has successfully supervised eight M.Sc. and several Ph.D., students.
4893SupratikKarDepartment of Chemistry, Physics and Atmospheric SciencesJackson State UniversityJacksonMSUnited States

Dr. Supratik Kar is a research associate at Jackson State University, Mississippi, USA. He has completed his B. Pharm. (2008) and M. Pharm. (2010) degree from Jadavpur University (Kolkata, India) securing first position in both degrees and earned his PhD (2015) from the Jadavpur University (Kolkata, India). He is a Former visiting researcher at the University of Gdańsk (Poland). Dr. Kar has been working and gaining experience in molecular modeling studies for ten years. He has published 50 research and review articles, 9 book chapters till date with h-index 20. He has also co-authored 2 QSAR related books in Academic press and Springer. He is also the Reviewer of more than 15 reputed journals.
4885KeiKunimasaDepartment of Thoracic OncologyOsaka International Cancer InstituteOsakaJapan

Dr. Kei Kunimasa, (born December 25, 1981, Hyogo, Japan), studied medicine at Osaka University, graduating with an M.D. in 2006. He later also received a Ph.D. (2016) in medical science from Kobe University. While a graduate student, he researched cell competition using Drosophila melanogaster and found Sas (stranded at second) controls cell competition between normal cell and neighboring cancer cell (Nature. 2017), and he also researched cancer metabolism under Tatsuya Nagano (Cancer Science. 2018). From 2017, he worked at Osaka International Cancer Institute as senior staff and researched clinical cancer genomics using next generation sequencing with human samples. He also won the fund from Japan Society for the Promotion of Science (JSJP)(2019) and Takeda science foundation(2019).
4878DanyiLuSchool of Pharmaceutical SciencesGuangzhou University of Chinese MedicineGuangzhouChinarohdy@163.com4892Mohammad A.KamalKing Fahd Medical Research CenterKing Abdulaziz UniversityJeddahSaudi Arabia

Dr. Mohammad Amjad Kamal is a Distinguished Adjunct Professor at the King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Saudi Arabia. He is leading a highly productive global collaborative research team based on Novel Global Community Educational Foundation (NGCEF), Australia. Dr. Kamal's biochemical research in the field of Alzheimer’s disease, Type 2 diabetes and leukemia has culminated in more than 380 publications in internationally respected journals. Dr. Kamal was awarded a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney. This three years highly competitive award funded his research on the "Inhibition of amido phosphoribosyltransferase by new antifolates". Amongst numerous projects, Dr. Kamal also collaborated on the molecular biological research project “Linkage of Alzheimer’s disease and Type 2 diabetes” at the University of Technology, Sydney. Moreover, he is serving as an EiC/regional/editorial member/guest editor of several reputed scientific journals on honorable basis.
4884NunoValeDepartment of Drug Sciences, Faculty of PharmacyUniversity of PortoPortoPortugal

Dr. Nuno Vale is an Invited Professor of Pharmacology (Pharmacokinetic and Drug Metabolism) at the Faculty of Pharmacy of the University of Porto. His research interest lies at the intersection between Biomedical Sciences and Pharmacology, namely on the development of new conjugates with peptides and nanoparticles for drug delivery in cancer and central nervous system. His main research focus is also on the Pharmacokinetic and Drug Metabolism of approved drugs for drug repurposing, and in PBPK Modeling and Drug-Drug Interactions.
4891SagnikChatterjeePharmaceutical Candidate OptimizationBristol-Myers SquibbNew YorkNYUnited States

Dr. Sagnik Chatterjee currently serves as a senior research investigator in BBRC, Bangalore. His group is working on impact of transporters in disposition, toxicity and efficacy of molecules, in normal and in disease conditions. He completed his M.S. (Pharm) from NIPER, Mohali, India in natural products chemistry (2005-2007) and then obtained his PhD degree from KU Leuven, Belgium in exploring drug-induced cholestasis (2010-2014). He developed and validated a sandwich- cultured hepatocyte-based system, with externally added bile acids, that is widely accepted and recommended by International Transporter Consortium. Before PhD he worked with AstraZeneca India, in their drug metabolism group (2007-2009). He has published in 9 peer-reviewed articles with present citations tally of 290.
4883Radislav VentsislavovNakovDepartment of GastroenterologyTsaritsa Yoanna University HospitalSofiaBulgaria

Dr. Nakov is a consultant gastroenterologist at Tsaritsa Yoanna University Hospital, Sofia. He obtained a doctorate (PhD) in Gastroenterology from the Medical University of Sofia. Dr. Nakov is a member of Young Talents Group and Education Committee at United European Gastroenterology (UEG), a course director of UEG Summer School and a president at Association for young hepatogastroenterologists in Bulgaria.
4888HuiDingSchool of Life Science and Technology, Center for Informational BiologyUniversity of Electronic Science and Technology of ChinaChengduChina

Dr. Hui Ding is an Associate Professor of Center for Informational Biology at University of Electronic Science and Technology of China. She received her PhD from Inner Mongolia University, P.R. China in 2009. Her research is in the areas of Systems Biology and theoretical biology. She has published over 60 peer-reviewed papers in SCI-indexed journals.
4882GianlucaIaniroDigestive Disease CenterFondazione Policlinico Universitario “A. Gemelli”RomeItaly

Dr. Ianiro received his medical degree in 2009 summa cum laude at the Catholic University of Rome. He got his trainingd in gastroenterology from the same University. He is currently gastroenterologist at the Digestive Disease Center of the Fondazione A. Gemelli IRCCS, Università Cattolica del Sacro Cuore in Rome, Italy. He is a key clinical and translational investigator focusing mainly on the field of intestinal microbiota with 99 peer reviewed publications including some of the best referral journal in Gastroenterology and Internal Medicine, including NEJM, Circulation, Annals of Internal Medicine, Gut, Nature Reviews Gastroenterology and Hepatology, Pharmacology & Therapeutics, Clinical Gastroenterology & Hepatology, Alimentary Pharmacology & Therapeutics, etc.). He was the secretary of two international consensus conferences on fecal microbiota transplantation. He was in the Young Talent Group, and now is in the Research Committee, of the UEG (United European Gastroenterology). Dr. Ianiro has received several research grants in support of his innovative research (the most recent from the Italian Ministry of Health as PI for a project entitled "Targeting gut microbiota to improve efficacy of immune checkpoint inhibitors in patients with advanced renal cell carcinoma").
4881Marcello FabioMaidaGastroenterology and Endoscopy UnitA.O. Ospedali Riuniti S. Elia-RaimondiCaltanissettaItaly

Dr. Marcello Maida graduated from the medical school at University of Palermo. He is a consultant gastroenterologist at S.Elia- Raimondi Hospital in Caltanissetta, Italy, member of the governing council of the Young Italian Gastroenterologists Association (AGGEI) and Director of the Multimedia Educational Platform of Italian Medical Schools of Gastroenterology (Gastrolearning). He is author of several scientific papers indexed on PubMed and published in impact factor journals. Dr. Maida’s research interests include several areas of liver diseases, including hepatocellular carcinoma, viral hepatitis, autoimmune liver diseases, cirrhosis and non-invasive evaluation of chronic liver diseases.
4895Saulo R.TintinoDepartamento de Ciências Físicas e BiológicasUniversidade Regional do CaririCratoBrazil

Dr. S.R. Tintino completed his graduation in Biological Sciences from the Regional University of Cairri. He further obtained a PhD in Biotechnology from the Federal University of Pernambuco. He is currently serving as a Substitute Professor at the Regional University of Cairri-URCA and he is a Coordinator of the Universal CNP project. He is also a member of the research group of the Laboratory of Microbiology and Molecular Biology. He is experienced in the area of Microbiology, with emphasis on antimicrobial activity of natural products and isolated substances and in the Genetics of Microorganisms with emphasis on mechanisms of inhibition of bacterial efflux pumps. He is a reviewer for several international journals.
4887JiayuZhangSchool of PharmacyBinzhou Medical UniversityYantaiChina

Professor/Dr. Jiayu Zhang received his Ph.D degree in pharmacognosy (Chemistry of Chinese Materia Medica) from Peking University. He is currently a professor at BIN ZHOU Medical University. During 2011-2019, he worked in Beijing University of Chinese Medicine, which is a famous University of traditional Chinese medicine in China. He is especially interested in metabolism and pharmacokinetics of traditional Chinese medicine. He has published more than 70 peer-reviewed papers.